Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREG randomized phase II study

BACKGROUND: Disease assessment for recurrent glioblastoma (GBM) represents a challenge, especially with the use of antiangiogenic agents. Moreover, validated neuroradiological predictors of outcome are lacking. Recently, the concept of early tumor shrinkage (ETS) has been developed to better assess...

Descripción completa

Detalles Bibliográficos
Autores principales: Brandes, Alba A., Finocchiaro, Gaetano, Zagonel, Vittorina, Reni, Michele, Fabi, Alessandra, Caserta, Claudia, Tosoni, Alicia, Eoli, Marica, Lombardi, Giuseppe, Clavarezza, Matteo, Paccapelo, Alexandro, Bartolini, Stefania, Cirillo, Luigi, Agati, Raffaele, Franceschi, Enrico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589683/
https://www.ncbi.nlm.nih.gov/pubmed/28903444
http://dx.doi.org/10.18632/oncotarget.15735

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589683/
https://www.ncbi.nlm.nih.gov/pubmed/28903444
http://dx.doi.org/10.18632/oncotarget.15735

Ejemplares similares